Serum Tumor Markers in Colorectal Cancer – Staging, Grading and Follow-Up

Serum Tumor Markers in Colorectal Cancer – Staging, Grading and Follow-Up

Early diagnosis of colorectal cancer, a frequent neoplasia in industrialized countries, permits curative surgery. In this study we assessed the clinical role of serum tumor markers determination in diagnosing, staging, and grading colorectal cancer; the role of carcinoembryonic antigen (CEA), CA 19-9, tissue polypeptide antigen (TPA) and CA 72-4 in colorectal cancer follow-up was also assessed. In 114 patients with colorectal cancer, the oncofetal antigen CEA was compared with the membrane-associated glycoproteins CA 19-9, CA 242, and CA 72-4 and with the cytokeratins TPA, tissue polypeptide-specific antigen (TPS) and tissue polypeptide monoclonal antigen (TPM). Overall, the most sensitive indices were TPA and TPS (67% and 7096, respectively). Tumor stage influenced the levels of CEA, CA 19-9, and TPA, but not those of TPS, while tumor grade influenced CEA and TPS, but not CA 72-4, TPA, and TPM. TPA was the most sensitive index in identifying early or well-differentiated colorectal cancers. The sensitivity was enhanced when this marker was determined in combination with CEA, in diagnosing both advanced and early colorectal tumors. Seventy-seven patients were followed up after therapy for at least 18 months. CEA was the most sensitive index of recurrence (58%); however, this sensitivity is too low to consider tumor markers useful in colorectal cancer follow-up.
Blood Markers for Early Detection of Colorectal Cancer – A systematic Review

Blood Markers for Early Detection of Colorectal Cancer – A systematic Review

Despite different available methods for colorectal cancer (CRC) screening and their proven benefits, morbidity, and mortality of this malignancy are still high, partly due to lowcompliance with screening. Minimally invasive tests based on the analysis of blood specimens may overcome this problem. The purpose of this reviewwas to give an overviewof published studies on blood markers aimed at the early detection of CRC and to summarize their performance characteristics. The PUBMED database was searched for relevant studies published until June 2006. Only studies with more than 20 cases and more than 20 controls were included. Information on the markers under study, on the underlying study populations, and on performance characteristics was extracted. Special attention was given to performance characteristics by tumor stage. Overall, 93 studies evaluating 70 different markers were included. Most studies were done on protein markers, but DNA markers and RNA markers were also investigated. Performance characteristics varied widely between different markers, but also between different studies using the same marker. Promising results were reported for some novel assays, e.g., assays based on SELDI-TOF MS or MALDI-TOF MS, for some proteins (e.g., soluble CD26 and bone sialoprotein) and also for some genetic assays (e.g., L6 mRNA), but evidence thus far is restricted to single studies with limited sample size and without further external validation. Larger prospective studies using study populations representing a screening population are needed to verify promising results. In addition, future studies should pay increased attention to the potential of detecting precursor lesions.
Comparison between CEA, CA 19-9 and CA 72-4 in Patients with Colorectal Cancer

Comparison between CEA, CA 19-9 and CA 72-4 in Patients with Colorectal Cancer

In Egypt, colorectal cancer (CRC) is one of the most common malignancies and represents 6.5% of cancers. The most important currently available tumor markers in CRC that provide diagnostic information to reduce mortality and morbidity are carcinoembryonic-antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and CA 72-4. The main objectives of the present work were to compare the serological tumor markers CEA, CA19-9 and CA 72-4 and to verify the effectiveness of each marker as a potential routine diagnostic test in CRC. Blood samples were collected from twenty five CRC patients then compared with thirty five normal blood samples from apparently healthy persons who were considered as controls. Serum of each sample was evaluated for the three tumor markers and assessed by ELISA technique Results: CA72-4 and CEA showed high statistically significant difference between CRC and controls, on the contrary CA19-9 showed a statistically insignificant between the studied groups. As for the results of the ROC curve, the sensitivity for using CA 72-4 parameter was 82.86%, the specificity was 100% and the highest AUC for CA72-4 denoting its performance as the preferred diagnostic routinetest among other markers mentioned above. Based on our findings, the results of this study indicated that the serum CEA is not a much more sensitive tumor marker than CA72-4. As well as the serum CA72-4 levels can be used in diagnosis of colon cancer and in need to be applied as a routine tumor marker.
Association of Serum Levels of CEA, CA 19.9, CA 125, CYFRA 21-1 and CA 72.4 and Disease Characteristics in Colorectal Cance

Association of Serum Levels of CEA, CA 19.9, CA 125, CYFRA 21-1 and CA 72.4 and Disease Characteristics in Colorectal Cance

Identifying predictive biomarkers for colorectal cancer would facilitate diagnosis and treatment of the disease. This study aimed to investigate the association of the serological biomarkers CEA, CA19–9, CA125, CYFRA21–1 and CA72–4 with patient characteristics and disease outcomes in colorectal cancer. Patients (N=373) with colorectal cancer were evaluated for the association of CEA, CA19–9, CA125, CYFRA21–1, and CA72–4 pre and post-surgery and at disease recurrence with demographics, disease characteristics including pathological types, degree of differentiation, invasion depth, abdominal lymph node metastasis, TMN stage, Dukes stage, location of cancer and metastasis, and disease outcomes. It was more common for a patient to express these markers prior to surgery and at disease recurrence than following surgery. Overall, the serum levels of CEA, CA19–9, CA125, CYFRA21–1, and CA72–4 were not associated with age, gender, pathological type and location of cancer (all P-values >0.05), but were associated with the poor tumor differentiation, higher tumor invasion, greater degree of abdominal lymph node metastasis, and higher TNM and Duke stage tumors (all P-values<0.01). CEA expression was associated with older ages (median age 65 years). Multivariate analysis indicated that CEA was correlated with overall survival and none of the markers correlated with disease recurrence. The expression of CEA, CA19–9, CA125, CYFRA21–1, and CA72–4 was associated with specific disease characteristics which tended to indicated more advanced disease and disease recurrence consistent with these biomarkers being useful for detecting colorectal cancer.
Colorectal Cancer Tumour Markers and Biomarkers – Recent Therapeutic Advances

Colorectal Cancer Tumour Markers and Biomarkers – Recent Therapeutic Advances

Colorectal cancer (CRC) is the second most commonly diagnosed cancer among females and third among males worldwide. It also contributes significantly to cancer-related deaths, despite the continuous progress in diagnostic and therapeutic methods. Biomarkers currently play an important role in the detection and treatment of patients with colorectal cancer. Risk stratification for screening might be augmented by finding new biomarkers which alone or as a complement of existing tests might recognize either the predisposition or early stage of the disease. Biomarkers have also the potential to change diagnostic and treatment algorithms by selecting the proper chemotherapeutic drugs across a broad spectrum of patients. There are attempts to personalise chemotherapy based on presence or absence of specific biomarkers. In this review, we update review published last year and describe our understanding of tumour markers and biomarkers role in CRC screening, diagnosis, treatment and follow-up. Goal of future research is to identify those biomarkers that could allow a non-invasive and cost- effective diagnosis, as well as to recognise the best prognostic panel and define the predictive biomarkers for available treatments.
Models of LR analysis in Tumor Markers for Colorectal Cancer Dx

Models of LR analysis in Tumor Markers for Colorectal Cancer Dx

We evaluated the application of three machine learning algorithms, including logistic regression, support vector machine and back-propagation neural network, for diagnosing congenital heart disease and colorectal cancer. By inspecting related serum tumor marker levels in colorectal cancer patients and healthy subjects, early diagnosis models for colorectal cancer were built using three machine learning algorithms to assess their corresponding diagnostic values. Except for serum alpha-fetoprotein, the levels of 11 other serum markers of patients in the colorectal cancer group were higher than those in the benign colorectal cancer group (P < 0.05). The results of logistic regression analysis indicted that individual detection of serum carcinoembryonic antigens, CA199, CA242, CA125, and CA153 and their combined detection was effective for diagnosing colorectal cancer. Combined detection had a better diagnostic effect with a sensitivity of 94.2% an specificity of 97.7%; combining serum carcinoembryonic antigens, CA199, CA242, CA125, and CA153, with the support vector machine diagnosis model and back-propagation, a neural network diagnosis model was built with diagnostic accuracies of 82 and 75%, sensitivities of 85 and 80%, and specificities of 80 and 70%, respectively. Colorectal cancer diagnosis models based on the three machine learning algorithms showed high diagnostic value and can help obtain evidence for the early diagnosis of colorectal cancer.